AI-powered search

What are the traditional SCC prognostic paradigms?

Featuring Darrell Rigel, MD, MS | Senior Clinical Advisor |

Clinical Professor of Dermatology 
New York University
Grossman School of Medicine
New York, NY 
Adjunct Professor
UT Southwestern Medical School 
Consultant Dermatologist, Cooper Clinic
Dallas, TX

| Published August 01, 2023


In the video, Dr. Darrell Rigel discusses the traditional prognostic paradigms for squamous cell carcinoma (SCC). Currently, the two commonly used criteria are the AJCC (American Joint Committee on Cancer) criteria and the Boston Women and Brigham's criteria. These criteria rely on assessing clinical and histopathologic factors such as the diameter of the lesion and the presence of perineural invasion, among other factors. However, Dr. Rigel points out that these traditional paradigms do not take into account genomic information. This is where the 40-GEP test comes into play. The 40-GEP test provides additional genomic information, which can be integrated into the prognosis assessment to improve accuracy. By incorporating genomic data, clinicians can gain valuable insights into the underlying genetic characteristics of SCC, leading to a more comprehensive and refined prognosis for patients. This advancement in prognostic evaluation may ultimately aid in better treatment decision-making and patient outcomes. 

Key Points 
  • Traditional SCC prognostic paradigms: AJCC criteria, Boston Women, and Brigham’s criteria. 
  • Assessment of prognosis for squamous cell carcinoma based on clinical and histopathologic factors. 
  • Factors used in traditional criteria include diameter of the lesion and perineural invasion involvement. 
  • Traditional methods lack consideration of genomics in prognosis assessment. 
  • The 40-GEP test provides additional genomic information for better and more accurate prognosis integration.

Related Media

Powered by Polaris TM

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved